Search

Your search keyword '"Ko, Young-Guk"' showing total 1,832 results
Start Over Author "Ko, Young-Guk" Publication Year Range Last 50 years
1,832 results on '"Ko, Young-Guk"'

2. Balloon-expandable cobalt chromium stent versus self-expandable nitinol stent for the Atherosclerotic Iliac Arterial Disease (SENS-ILIAC Trial) Trial: a randomized controlled trial

Author

Choi, Woong Gil, Rha, Seung-Woon, Choi, Byoung Geol, Park, Soohyung, Kim, Ji Bak, Kang, Dong Oh, Choi, Cheol Ung, Seo, Yong Sung, Cho, Yoon Hyung, Park, Sang Ho, Lee, Seung Jin, Ko, Young Guk, Her, Ae-Young, Kim, Sang Min, Kim, Ki Chang, Cho, Jang Hyun, Kang, Won Yu, Kim, Joo Han, Kim, Min Woong, Kim, Do Hoi, Bae, Jang Ho, Ahn, Ji Hoon, Jo, Sang Cheol, Seo, Jae Bin, Jung, Woo Young, and Park, Sang Min

Published
2024
Full Text
View/download PDF

3. Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea

Author

Hong, Sung-Jin, Lee, Seung-Jun, Lee, Sang-Hyup, Lee, Jong-Young, Cho, Deok-Kyu, Kim, Jin Won, Kim, Sang Min, Hur, Seung-Ho, Heo, Jung Ho, Jang, Ji-Yong, Koh, Jin Sin, Won, Hoyoun, Lee, Jun-Won, Hong, Soon Jun, Kim, Dong-Kie, Choe, Jeong Cheon, Lee, Jin Bae, Kim, Soo-Joong, Yang, Tae-Hyun, Lee, Jung-Hee, Hong, Young Joon, Ahn, Jong-Hwa, Lee, Yong-Joon, Ahn, Chul-Min, Kim, Jung-Sun, Ko, Young-Guk, Choi, Donghoon, Hong, Myeong-Ki, Jang, Yangsoo, and Kim, Byeong-Keuk

Published
2024
Full Text
View/download PDF

7. Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial

Author

Hong, Sung-Jin, Lee, Seung-Jun, Suh, Yongsung, Yun, Kyeong Ho, Kang, Tae Soo, Shin, Sanghoon, Kwon, Sung Woo, Lee, Jun-Won, Cho, Deok-Kyu, Park, Jong-Kwan, Bae, Jang-Whan, Kang, Woong Cheol, Kim, Seunghwan, Lee, Yong-Joon, Ahn, Chul-Min, Kim, Jung-Sun, Kim, Byeong-Keuk, Ko, Young-Guk, Choi, Donghoon, Jang, Yangsoo, and Hong, Myeong-Ki

Published
2024
Full Text
View/download PDF

9. Moderate-intensity statin plus ezetimibe vs high-intensity statin according to baseline LDL-C in the treatment of atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING randomized trial

Author

Lee, Bom, Hong, Sung-Jin, Rha, Seung-Woon, Heo, Jung Ho, Hur, Seung-Ho, Choi, Hyun Hee, Kim, Kyung-Jin, Kim, Ju Han, Kim, Hyun Kuk, Kim, Ung, Choi, Yu Jeong, Lee, Yong-Joon, Lee, Seung-Jun, Ahn, Chul-Min, Ko, Young-Guk, Kim, Byeong-Keuk, Choi, Donghoon, Hong, Myeong-Ki, Jang, Yangsoo, and Kim, Jung-Sun

Published
2023
Full Text
View/download PDF

11. Association of Prophylactic Distal Perfusion Cannulation With Mortality in Patients Receiving Venoarterial Extracorporeal Membrane Oxygenation

Author

Lee, Hyeok-Hee, Jang, Woo Jin, Ahn, Chul-Min, Chun, Woo Jung, Oh, Ju Hyeon, Park, Yong Hwan, Lee, Seung-Jun, Hong, Sung-Jin, Yang, Jeong Hoon, Kim, Jung-Sun, Kim, Hyeon Chang, Kim, Byeong-Keuk, Yu, Cheol Woong, Kim, Hyun-Joong, Bae, Jang-Whan, Ko, Young-Guk, Choi, Donghoon, Gwon, Hyeon-Cheol, Hong, Myeong-Ki, and Jang, Yangsoo

Published
2023
Full Text
View/download PDF

13. Treat-to-target versus high-intensity statin treatment in patients with or without diabetes mellitus: a pre-specified analysis from the LODESTAR trial

Author

Hong, Myeong-Ki, Choi, Donghoon, Ko, Young-Guk, Kim, Byeong-Keuk, Kim, Jung-Sun, Ahn, Chul-Min, Hong, Sung-Jin, Lee, Seung-Jun, Lee, Yong-Joon, Hong, Bum-Kee, Kwon, Hyuck Moon, Kim, Jong-Youn, Min, Pil Ki, Yoon, Young Won, Lee, Byoung Kwon, Rim, Se-Joong, Choi, Eui-Young, CholKang, Woong, Oh, Pyung Chun, Lee, Jong-Young, Lee, Jin-Bae, Kim, Kee Sik, Choi, Ji Yong, Ryu, Jae Kean, Hong, Seung Pyo, Kim, Chang Yeon, Yang, Tae-Hyun, Cho, Hyung-Jin, Yoon, Junghan, Ahn, Min-Soo, Ahn, Sung Gyun, Lee, Jun-Won, Son, Jung-Woo, Jang, Yangsoo, Yoon, Hyuck-Jun, Lee, Cheol Hyun, Hwang, Jongmin, Cho, Yun-Kyeong, Hur, Seung-Ho, Han, Seongwook, Nam, Chang-Wook, Kim, Hyoungseop, Park, Hyoung-Seob, Kim, In-Cheol, Cho, Yun-Hyeong, Jeong, Hyeon-Ju, Kim, Jin-Ho, Lim, Chewan, Suh, Yongsung, Hwang, Eui Seok, Lee, Ji Hyun, Lee, Sung Yun, Kwon, Sung Uk, Kim, Song-Yi, Park, Keun-Ho, Ki, Hyun Kuk, and Kang, Woong Chol

Published
2023
Full Text
View/download PDF

14. Perioperative Antiplatelet Strategy in Patients Undergoing Noncardiac Surgery Within One Year After Percutaneous Coronary Intervention

Author

Lee, Sang-Hyup, Kim, Choongki, Shin, Sanghoon, Kim, Hyeongsoo, Park, Jong-Kwan, Oh, Seung-Jin, Ahn, Sung Gyun, Cho, Sungsoo, Lee, Oh-Hyun, Moon, Jae Youn, Won, Hoyoun, Suh, Yongsung, Cho, Yun-Hyeong, Cho, Jung Rae, Lee, Byoung-Kwon, Lee, Yong-Joon, Lee, Seung-Jun, Hong, Sung-Jin, Shin, Dong-Ho, Ahn, Chul-Min, Kim, Byeong-Keuk, Ko, Young-Guk, Choi, Donghoon, Hong, Myeong-Ki, Jang, Yangsoo, and Kim, Jung-Sun

Published
2023
Full Text
View/download PDF

16. Efficacy and safety of moderate-intensity statin with ezetimibe combination therapy in patients after percutaneous coronary intervention: a post-hoc analysis of the RACING trial

Author

Park, Jong-Il, Lee, Seung-Jun, Lee, Yong-Joon, Hong, Sung-Jin, Ahn, Chul-Min, Kim, Byeong-Keuk, Ko, Young-Guk, Choi, Donghoon, Hong, Myeong-Ki, Kim, Jung-Sun, Hong, Bum-Kee, Lee, Jung-Hee, Kim, Ung, Cho, Yun-Hyeong, Shin, Won-Yong, Lim Jang, Sang-Wook Yangsoo, Kang, Woong-Chol, Park Jung, Yongwhi Young Hoon, Lee, Sung-Yoon, Kim, Kyoung Jin, Hong, Soon-Jun, Yun, Kyeong Ho, Heo, Jung Ho, Rha, Seung-Woon, Choi, Woong Gil, Lee, Wang Soo Lee, Jung, Jinok, Choi, Sunghoon, Cho, Youn Haeng, Park, Woo Jung, Youn, Changhwan, Hur, Seung Ho, Choi, Hyun Hee, Kim, Ju Han, Kim, Hyun Kuk, Choi, Yu-Jung, Lim, Sang-Wook, Park, Yongwhi, and Jang, Yangsoo

Published
2023
Full Text
View/download PDF

17. Tratamiento antiagregante plaquetario doble tras la intervención coronaria percutánea del tronco coronario izquierdo

Author

Cho, Sungsoo, Kang, Do-Yoon, Kim, Jung-Sun, Park, Duk-Woo, Kim, In-Soo, Kang, Tae Soo, Ahn, Jung-Min, Lee, Pil Hyung, Kang, Soo-Jin, Lee, Seung-Whan, Kim, Young-Hak, Lee, Cheol Whan, Park, Seong-Wook, Lee, Seung-Jun, Hong, Sung-Jin, Ahn, Chul-Min, Kim, Byeong-Keuk, Ko, Young-Guk, Choi, Donghoon, Jang, Yangsoo, Hong, Myeong-Ki, and Park, Seung-Jung

Published
2023
Full Text
View/download PDF

19. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial

Author

Kim, Byeong-Keuk, Hong, Sung-Jin, Lee, Yong-Joon, Hong, Soon Jun, Yun, Kyeong Ho, Hong, Bum-Kee, Heo, Jung Ho, Rha, Seung-Woon, Cho, Yun-Hyeong, Lee, Seung-Jun, Ahn, Chul-Min, Kim, Jung-Sun, Ko, Young-Guk, Choi, Donghoon, Jang, Yangsoo, and Hong, Myeong-Ki

Published
2022
Full Text
View/download PDF

23. Drug-coated balloon versus drug-eluting stent for femoropopliteal total occlusions: intraluminal versus subintimal approaches.

Author

Kim, Yong Hoon, Her, Ae-Young, Ko, Young-Guk, Ahn, Chul-Min, Lee, Seung-Jun, Hong, Myeong-Ki, Yu, Cheol Woong, Lee, Jae-Hwan, Lee, Seung Whan, Youn, Young Jin, Yoon, Chang-Hwan, Rha, Seung-Woon, Min, Pil-Ki, Choi, Seung-Hyuk, Chae, In-Ho, Choi, Donghoon, Kang, Woong Chol, Her, Sung-Ho, Koh, Yoon Seok, and Hwang, Byung-Hee

Subjects
ARTERIAL diseases, BALLOON occlusion, AMPUTATION, COMPARATIVE studies
Abstract

Because there is a lack of comparative studies assessing drug-coated balloon (DCB) and drug-eluting stent (DES) outcomes with respect to intraluminal (IL) and subintimal (SI) approaches in femoropopliteal (FP) total occlusive lesions, we compared the outcomes between DCB (including bailout stenting) and DES treatments for this lesion. A total of 487 limbs (434 patients) were divided into the IL (n = 344, DCB: n = 268, DES: n = 76) and SI (n = 143, DCB: n = 83, DES: n = 60) approach groups. The primary outcome was a major adverse limb event (MALE), defined as above-ankle amputation or repeat revascularization of the index limb. Secondary outcomes included clinically driven target lesion revascularization (TLR), loss of clinical patency, and all-cause death. After adjustment, in each IL and SI approach, the 2-year rates of MALE (p = 0.180 and p = 0.236, respectively), TLR, loss of clinical patency, and all-cause death were similar between the DCB and DES groups. In the DCB and DES groups, both primary and secondary outcomes were similar between the IL and SI approaches. DCB and DES strategies for patients presenting with FP total occlusive lesions demonstrated similar outcomes regardless of the IL or SI approach. Clinical Trial Registration: NCT02748226. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Ticagrelor monotherapy for acute coronary syndrome: an individual patient data meta-analysis of TICO and T-PASS trials.

Author

Lee, Yong-Joon, Shin, Sanghoon, Kwon, Sung Woo, Suh, Yongsung, Yun, Kyeong Ho, Kang, Tae Soo, Lee, Jun-Won, Cho, Deok-Kyu, Park, Jong-Kwan, Bae, Jang-Whan, Kang, Woong Cheol, Kim, Seunghwan, Lee, Seung-Jun, Hong, Sung-Jin, Ahn, Chul-Min, Kim, Jung-Sun, Kim, Byeong-Keuk, Ko, Young-Guk, Choi, Donghoon, and Jang, Yangsoo

Subjects
ACUTE coronary syndrome, PLATELET aggregation inhibitors, MYOCARDIAL infarction, CLINICAL trials, TICAGRELOR
Abstract

Background and Aims In patients with acute coronary syndrome (ACS), dual antiplatelet therapy (DAPT) with aspirin and a potent P2Y12 inhibitor is recommended for 12 months after drug-eluting stent (DES) implantation. Monotherapy with a potent P2Y12 inhibitor after short-term DAPT is an attractive option to better balance the risks of ischaemia and bleeding. Therefore, this study evaluated the efficacy and safety of ticagrelor monotherapy after short-term DAPT, especially in patients with ACS. Methods Electronic databases were searched from inception to 11 November 2023, and for the primary analysis, individual patient data were pooled from the relevant randomized clinical trials comparing ticagrelor monotherapy after short-term (≤3 months) DAPT with ticagrelor-based 12-month DAPT, exclusively in ACS patients undergoing DES implantation. The co-primary endpoints were ischaemic endpoint (composite of all-cause death, myocardial infarction, or stroke) and bleeding endpoint [Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding] at 1 year. Results Individual patient data from two randomized clinical trials including 5906 ACS patients were analysed. At 1 year, the primary ischaemic endpoint did not differ between the ticagrelor monotherapy and ticagrelor-based DAPT groups [1.9% vs. 2.5%; adjusted hazard ratio (HR) 0.79; 95% confidence interval (CI) 0.56–1.13; P =.194]. The incidence of the primary bleeding endpoint was lower in the ticagrelor monotherapy group (2.4% vs. 4.5%; adjusted HR 0.54; 95% CI 0.40–0.72; P <.001). The results were consistent in a secondary aggregate data meta-analysis including the ACS subgroup of additional randomized clinical trials which enrolled patients with ACS as well as chronic coronary syndrome. Conclusions In ACS patients undergoing DES implantation, ticagrelor monotherapy after short-term DAPT was associated with less major bleeding without a concomitant increase in ischaemic events compared with ticagrelor-based 12-month DAPT. Study registration PROSPERO (ID: CRD42023476470). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Intravascular ultrasound-guided drug-coated balloon angioplasty for femoropopliteal artery disease: a clinical trial.

Author

Ko, Young-Guk, Lee, Seung-Jun, Ahn, Chul-Min, Lee, Sang-Hyup, Lee, Yong-Joon, Kim, Byeong-Keuk, Hong, Myeong-Ki, Jang, Yangsoo, Kim, Tae-Hoon, Park, Ha-Wook, Jang, Ji Yong, Lee, Jae-Hwan, Park, Jae-Hyeong, Kim, Su Hong, Im, Eui, Park, Sang-ho, Choi, Donghoon, and investigators, IVUS-DCB

Subjects
INTRAVASCULAR ultrasonography, TRANSLUMINAL angioplasty, ENDOVASCULAR surgery, PERIPHERAL vascular diseases, ARTERIAL diseases
Abstract

Background and Aims Drug-coated balloons (DCBs) have demonstrated favourable outcomes following endovascular therapy for femoropopliteal artery (FPA) disease. However, uncertainty remains whether the use of intravascular ultrasound (IVUS) can improve the outcomes of DCBs. Methods This prospective, multicentre, randomized trial, conducted at seven centres in South Korea, compared the outcomes of IVUS-guided vs. angiography-guided angioplasty for treating FPA disease with DCBs. Patients were assigned to receive IVUS-guided (n = 119) or angiography-guided (n = 118) angioplasty using DCBs. The primary endpoint was 12-month primary patency. Results Between May 2016 and August 2022, 237 patients were enrolled and 204 (86.0%) completed the trial (median follow-up; 363 days). The IVUS guidance group showed significantly higher primary patency [83.8% vs. 70.1%; cumulative difference 19.6% (95% confidence interval 6.8 to 32.3); P =.01] and increased freedom from clinically driven target lesion revascularization [92.4% vs. 83.0%; difference 11.6% (95% confidence interval 3.1 to 20.1); P =.02], sustained clinical improvement (89.1% vs. 76.3%, P =.01), and haemodynamic improvement (82.4% vs. 66.9%, P =.01) at 12 months compared with the angiography guidance group. The IVUS group utilized larger balloon diameters and pressures for pre-dilation, more frequent post-dilation, and higher pressures for post-dilation, resulting in a greater post-procedural minimum lumen diameter (3.90 ± 0.59 vs. 3.71 ± 0.73 mm, P =.03). Conclusions Intravascular ultrasound guidance significantly improved the outcomes of DCBs for FPA disease in terms of primary patency, freedom from clinically driven target lesion revascularization, and sustained clinical and haemodynamic improvement at 12 months. These benefits may be attributed to IVUS-guided optimization of the lesion before and after DCB treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Effect of rosuvastatin versus atorvastatin on new-onset diabetes mellitus in patients treated with high-intensity statin therapy for coronary artery disease: a post-hoc analysis from the LODESTAR randomized clinical trial.

Author

Hong, Sung-Jin, Lee, Yong-Joon, Kang, Woong Chol, Hong, Bum-Kee, Lee, Jong-Young, Lee, Jin-Bae, Yang, Tae-Hyun, Yoon, Junghan, Lee, Seung-Jun, Ahn, Chul-Min, Kim, Jung-Sun, Kim, Byeong-Keuk, Ko, Young-Guk, Choi, Donghoon, Jang, Yangsoo, and Hong, Myeong-Ki

Subjects
LDL cholesterol, STATINS (Cardiovascular agents), CORONARY artery disease, ATORVASTATIN, ROSUVASTATIN
Abstract

Background: The impact of rosuvastatin versus atorvastatin on new-onset diabetes mellitus (NODM) among patients treated with high-intensity statin therapy for coronary artery disease (CAD) remains to be clarified. This study aimed to evaluate the risk of NODM in patients with CAD treated with rosuvastatin compared to atorvastatin in the randomized LODESTAR trial. Methods: In the LODESTAR trial, patients with CAD were randomly assigned to receive either rosuvastatin or atorvastatin using a 2-by-2 factorial randomization. In this post-hoc analysis, the 3-year incidence of NODM was compared between rosuvastatin and atorvastatin treatment in the as-treated population with high-intensity statin therapy as the principal population of interest. Results: Among 2932 patients without diabetes mellitus at baseline, 2377 were included in the as-treated population analysis. In the as-treated population with high-intensity statin therapy, the incidence of NODM was not significantly different between the rosuvastatin and atorvastatin groups (11.4% [106/948] versus 8.8% [73/856], hazard ratio [HR] = 1.32, 95% confidence interval [CI] = 0.98 to 1.77, P = 0.071). When the risk of NODM with rosuvastatin versus atorvastatin was assessed according to the achieved low-density lipoprotein cholesterol (LDL-C) level, the risk of NODM began to increase at a LDL-C level below 70 mg/dL. The incidence of NODM was significantly greater in the rosuvastatin group than it was in the atorvastatin group when the achieved LDL-C level was < 70 mg/dL (13.9% versus 8.0%; HR = 1.79, 95% CI 1.18 to 2.73, P = 0.007). Conclusions: Among CAD patients receiving high-intensity statin therapy, the incidence of NODM was not significantly different between rosuvastatin and atorvastatin. However, a drug effect of the statin type on NODM was observed when the achieved LDL-C level was < 70 mg/dL. Trial registration: ClinicalTrials.gov, Identifier: NCT02579499. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Continuous Renal Replacement Therapy and Extracorporeal Membrane Oxygenation in Patients with Cardiogenic Shock: A Multicenter Observational Study: Results from the RESCUE Registry

Author

Lim, Chewan, primary, Chung, Young Hak, additional, Ahn, Chul-Min, additional, Cho, Sungsoo, additional, Yang, Jeong Hoon, additional, Kang, Tae Soo, additional, Lee, Sang-Hyup, additional, Lee, Yong Joon, additional, Lee, Seung Jun, additional, Hong, Sung Jin, additional, Kim, Jung Sun, additional, Kim, Byeong Keuk, additional, Ko, Young Guk, additional, Choi, Donghoon, additional, Gwon, Hyeon Cheol, additional, Hong, Myeong Ki, additional, and Jang, Yangsoo, additional

Published
2024
Full Text
View/download PDF

35. Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Patients With ST-Segment Elevation Myocardial Infarction

Author

Lee, Seung-Jun, Cho, Jae Young, Kim, Byeong-Keuk, Yun, Kyeong Ho, Suh, Yongsung, Cho, Yun-Hyeong, Kim, Yong Hoon, Her, Ae-Young, Cho, Sungsoo, Jeon, Dong Woon, Yoo, Sang-Yong, Cho, Deok-Kyu, Hong, Bum-Kee, Kwon, Hyuck Moon, Hong, Sung-Jin, Ahn, Chul-Min, Shin, Dong-Ho, Nam, Chung-Mo, Kim, Jung-Sun, Ko, Young-Guk, Choi, Donghoon, Hong, Myeong-Ki, and Jang, Yangsoo

Published
2021
Full Text
View/download PDF

38. Treat-to-target or high-intensity statin treatment in older adults with coronary artery disease: a post hoc analysis of the LODESTAR trial.

Author

Lee, Seung-Jun, Lee, Jin-Bae, Yang, Tae-Hyun, Kang, Woong Chol, Lee, Jong-Young, Lee, Yong-Joon, Hong, Sung-Jin, Ahn, Chul-Min, Kim, Jung-Sun, Kim, Byeong-Keuk, Ko, Young-Guk, Hong, Bum-Kee, Choi, Donghoon, Yoon, Junghan, Jang, Yangsoo, Hong, Myeong-Ki, and investigators, for the LODESTAR

Subjects
MYOCARDIAL infarction risk factors, MORTALITY risk factors, PATIENT safety, RESEARCH funding, SECONDARY analysis, TREATMENT effectiveness, DESCRIPTIVE statistics, LDL cholesterol, AGE distribution, MYOCARDIAL revascularization, STATINS (Cardiovascular agents), DRUG efficacy, CORONARY artery disease, CONFIDENCE intervals, STROKE, EVALUATION, DISEASE risk factors, OLD age
Abstract

Background The optimal statin treatment strategy that is balanced for both efficacy and safety has not been clearly determined in older adults with coronary artery disease (CAD). Methods In the post hoc analysis of the LODESTAR (low-density lipoprotein cholesterol-targeting statin therapy versus intensity-based statin therapy in patients with coronary artery disease) trial, the impact between a treat-to-target strategy versus a high-intensity statin therapy strategy was compared in older adults (aged 75 years or older). The goal of treat-to-target low-density lipoprotein cholesterol (LDL-C) level was 50–70 mg/dl. The primary endpoint comprised the three-year composite of all-cause death, myocardial infarction, stroke or coronary revascularisation. Results Among 4,400 patients with CAD enrolled in the LODESTAR trial, 822 (18.7%) were aged 75 years or older. Poor clinical outcomes and risk factors for atherosclerosis were more frequently observed in older adults than in younger population (<75 years old). Among these older adults with CAD, the prescription rate of high-intensity statin was significantly lower in the treat-to-target strategy group throughout the study period (P  < 0.001). The mean LDL-C level for three years was 65 ± 16 mg/dl in the treat-to-target strategy group and 64 ± 18 mg/dl in the high-intensity statin group (P  = 0.34). The incidence of primary endpoint occurrence was 10.9% in the treat-to-target strategy group and 12.0% in the high-intensity statin group (hazard ratio 0.92, 95% confidence interval 0.61–1.38, P  = 0.69). Conclusions High-intensity statin therapy is theoretically more necessary in older adults because of worse clinical outcomes and greater number of risk factors for atherosclerosis. However, the primary endpoint occurrence with a treat-to-target strategy with an LDL-C goal of 50–70 mg/dl was comparable to that of high-intensity statin therapy and reduced utilisation of a high-intensity statin. Taking efficacy as well as safety into account, adopting a tailored approach may be considered for this high-risk population. Trial Registration ClinicalTrials.gov , NCT02579499. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. Culprit-only versus multivessel or complete versus incomplete revascularization in patients with non-ST-segment elevation myocardial infarction and multivessel disease who underwent successful percutaneous coronary intervention using newer-generation drug-eluting stents

Author

Kim, Yong Hoon, Her, Ae-Young, Jeong, Myung Ho, Kim, Byeong-Keuk, Hong, Sung-Jin, Kim, Seunghwan, Ahn, Chul-Min, Kim, Jung-Sun, Ko, Young-Guk, Choi, Donghoon, Hong, Myeong-Ki, and Jang, Yangsoo

Published
2020
Full Text
View/download PDF

50. Assessing the Clinical Impact of Cardiac Intensivists in Adult Cardiac Care Units: Results from the RESCUE registry

Author

Bae, Dae-Hwan, primary, Lee, Sang Yeub, additional, Bae, Jang-Whan, additional, Yang, Jeong Hoon, additional, Ko, Young-Guk, additional, Ahn, Chul-Min, additional, Yu, Cheol Woong, additional, Chun, Woo Jung, additional, Jang, Woo Jin, additional, Kim, Hyun-Joong, additional, Kim, Bum Sung, additional, Kwon, Sung Uk, additional, Kim, Je Sang, additional, Lee, Wang Soo, additional, Jeong, Jin-Ok, additional, Park, Sang-Don, additional, Lim, Seong-Hoon, additional, Cho, Sungsoo, additional, and Gwon, Hyeon-Cheol, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results